Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: CAH stock price vs NXPI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NXPI's multiple
Needs NXPI P/E.
Implied fair value · at CAH's multiple
Needs CAH P/E.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CAH FY 2026 (ended Jun 30, 2026) · NXPI FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Cardinal Health, Inc. · implied price per share
Bear
-$337.14
Base
-$396.63
Bull
-$456.13
NXP Semiconductors N.V. · implied price per share
Bear
$89.63
Base
$105.45
Bull
$121.26
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-3.08x
1.11x
Net debt / EBITDA
Leverage against operating earnings
0.99x
1.90x
Cash and equivalents
Liquid reserves on the balance sheet
$5.06B
$3.27B
Total debt
Interest-bearing obligations outstanding
$8.89B
$11.18B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MCKESSON CORP
CAH vs MCK
AmerisourceBergen Corporation
CAH vs ABC
Walgreens Boots Alliance, Inc.
CAH vs WBA
CVS Health Corporation
CAH vs CVS
HENRY SCHEIN INC
CAH vs HSIC
Qualcomm Incorporated
CAH vs QCOM
Broadcom Inc.
CAH vs AVGO
Texas Instruments Incorporated
CAH vs TXN
NVIDIA Corporation
CAH vs NVDA
Intel Corporation
CAH vs INTC
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe CAH can materially re-accelerate margins or justify a richer multiple despite its 1.0% operating margin, then hold; otherwise, reduce exposure or avoid adding because the current price implies -7.2% downside and CAH looks fundamentally weaker than NXPI on profitability.
CAH's current price of $238.94 is above the P/E-implied value of $221.78, implying a -7.2% downside. The valuation case looks stretched versus NXPI set because CAH trades at 37.0x P/E with only 0.3x P/S, while NXPI trades at 34.4x P/E and 5.6x P/S.
Supporting Metrics
